This Week in Obstetrics & Gynecology — May 28, 2026

Welcome to This Week in Obstetrics & Gynecology. This week we're covering 10 notable papers spanning gynecologic oncology, advances in reproductive medicine, and key issues in general obstetrics. Let's dive in.

Gynecologic Oncology

We'll start this week in gynecologic oncology, with papers ranging from preoperative imaging to the basic science of treatment resistance.

First, from *Ultrasound in Obstetrics & Gynecology*, we have the primary results of the CANNES trial [4]. This was a prospective, multicenter study designed to see if ultrasound is non-inferior to PET/CT and diffusion-weighted MRI for the preoperative assessment of pelvic lymph nodes in cervical cancer. In 120 patients, investigators compared imaging results to the gold standard of histopathology.

Results For detecting macrometastases, the diagnostic accuracy of ultrasound was 85.8%, compared to 84.2% for PET/CT and 86.1% for DW-MRI. The statistical analysis confirmed that ultrasound was non-inferior to both PET/CT and DW-MRI. This is an important, practice-affirming finding, suggesting that in experienced hands, high-quality ultrasound can be a primary, accessible, and cost-effective tool for staging cervical cancer, performing on par with more complex imaging modalities.

Building on the theme of prevention and screening, a commentary in *Obstetrics & Gynecology* makes a compelling case for why gynecologists must become anal cancer-prevention specialists [10]. The authors note that anal cancer incidence is rising, particularly among older women, a population frequently under our care. Given the shared human papillomavirus etiology with cervical cancer, the piece argues that gynecologists are uniquely positioned with a workforce-ready skillset to screen for and treat anal cancer precursors. This represents a logical extension of our current practice to address a preventable malignancy.

Shifting to the molecular level of oncology, two papers explore mechanisms of treatment resistance. First, a study in *Science Translational Medicine* investigates how genomic instability in high-grade serous ovarian cancer can paradoxically lead to immunosuppression and PARP inhibitor resistance [3]. The researchers used single-cell analysis to find that genomically unstable tumors activate a pathway called STING, which in turn causes the tumor to secrete WNT proteins. This reprograms surrounding fibroblasts into a specific type, called POSTN-positive myofibroblasts. These specialized fibroblasts then create an immunosuppressive microenvironment that blunts the effect of PARP inhibitors. The key takeaway is that this POSTN-dependent pathway is a potential therapeutic target. In their models, blocking POSTN reinvigorated the immune response and restored sensitivity to PARP inhibitors.

Finally, a fundamental study in *Nature* uncovers a new metabolic pathway that drives DNA repair, which is critical for how cancers respond to chemotherapy [2]. Researchers found that the metabolite alpha-ketoglutarate is essential for synthesizing carnitine. This carnitine synthesis pathway, in turn, is required for the histone acetylation needed to perform homologous recombination DNA repair. In patient samples, high levels of a key enzyme in this pathway, TMLHE, correlated with worse progression-free survival after treatment with DNA-damaging agents. This work identifies a novel metabolic vulnerability; by targeting carnitine synthesis, it may be possible to induce a state of DNA repair deficiency in otherwise proficient tumors, making them more sensitive to treatments like PARP inhibitors or chemotherapy.

Reproductive Endocrinology and Infertility

Turning now to reproductive medicine, two papers this week address both the techniques we use and the potential long-term outcomes of assisted reproduction.

First, a systematic review and meta-analysis in *Human Reproduction* asks a critical question: does intracytoplasmic sperm injection, or ICSI, outperform conventional IVF in couples *without* severe male factor infertility? [8] The analysis pooled data from six randomized controlled trials.

The Study Based on high-quality evidence, the answer is no. For couples without severe male factor, ICSI did not improve the live birth rate, with rates of 32.8% for ICSI versus 34.5% for conventional IVF. It also did not improve the cumulative live birth rate. The authors conclude that based on current evidence, ICSI should not be routinely recommended for indications other than severe male infertility. This directly challenges the widespread use of ICSI for other reasons, suggesting it adds cost and complexity without a clear benefit in this population.

While that paper focuses on the immediate outcome of ART, a study in the *American Journal of Obstetrics and Gynecology* looks at potential long-term genomic effects [6]. Investigators hypothesized that IVF may act as an embryonic stressor that alters mobile genetic elements known as Long Interspersed Nuclear Elements, or LINE-1s. They performed whole genome sequencing on cord blood from 33 IVF and 42 naturally conceived neonates. They found that IVF-conceived offspring had a significantly higher global content of these LINE-1 elements. This finding was confirmed in three sibling pairs with identical genetic backgrounds, where the IVF-conceived sibling consistently had higher LINE-1 levels. Importantly, the sites of these genomic changes were significantly enriched near genes implicated in metabolic, cardiovascular, neuropsychiatric, and neoplastic diseases — conditions for which IVF-conceived individuals may have elevated risks. This provides preliminary evidence of a potential genomic mechanism linking the IVF process to long-term health, and suggests that continued attention to genomic integrity in this population is warranted.

General Obstetrics and Foundational Science

In general obstetrics, we have a large cohort study on postpartum mental health and a preclinical study with implications for a common labor and delivery intervention.

The study on mental health, published in *Obstetrics & Gynecology*, used a national insurance database to look at over 934,000 births in the United States [9]. The goal was to evaluate the association between mode of delivery and new postpartum psychiatric conditions within six months of delivery.

Results Compared with spontaneous vaginal births, the risk of a new postpartum psychiatric diagnosis was significantly higher after all modes of cesarean delivery. The risk was increased by about 20% for planned cesareans, about 16% for unplanned cesareans, and about 26% for unplanned cesareans that occurred after a failed operative vaginal delivery attempt. Interestingly, a successful operative vaginal delivery was not associated with any increased risk compared to a spontaneous vaginal birth. These results from a very large cohort suggest that cesarean delivery itself is a risk factor for postpartum psychiatric conditions and warrants closer surveillance for all patients who undergo one.

Next, from the *American Journal of Obstetrics and gynecology*, a study in a rodent model challenges our thinking on magnesium sulfate dosing for fetal neuroprotection [7]. While antenatal magnesium is standard for pregnancies at risk of preterm birth, the optimal dose is unknown, with ACOG-endorsed regimens varying seven-fold. In a rat model of maternal inflammation, researchers compared a low-dose magnesium regimen, equivalent to a 4-gram loading dose in humans, to a high-dose regimen. Both the low- and high-dose magnesium protocols were equally effective at reducing key pro-inflammatory cytokines in the fetal brain and placenta, bringing them down to baseline levels. This preclinical evidence suggests that a reduced magnesium exposure may be sufficient for neuroprotection and strongly supports the need for clinical trials to compare reduced-duration protocols in humans.

Finally, we'll touch on two papers from the *Nature* family of journals. A landmark paper in *Nature* presents a spatiotemporal transcriptome atlas of human embryos after gastrulation [1]. Using advanced sequencing technology on embryos from Carnegie stage 12 to 23, the researchers created a comprehensive map of gene expression during organogenesis, providing an unprecedented resource for understanding human development and the origins of congenital disease. And a commentary in *Nature Medicine* explores how disease nomenclature shapes diagnosis, research, and patient lives [5]. While the full abstract was not available, the piece raises important questions about the power of the words we use in medicine.

Editor's Pick

If you only have time for one paper this week, make it the systematic review and meta-analysis on ICSI versus conventional IVF in *Human Reproduction* [8]. Based on high-quality evidence from randomized trials, it concludes that for couples without severe male factor infertility, ICSI provides no benefit in live birth or cumulative live birth rates, arguing against its routine use in this population.

Clinical Bottom Line

Here are the key takeaways from this week in Obstetrics & Gynecology.

First, from the CANNES trial, expert transvaginal ultrasound is non-inferior to PET/CT for the preoperative assessment of pelvic lymph nodes in cervical cancer, supporting its use as a primary imaging modality [4].

Second, for couples without severe male factor infertility, high-quality evidence shows ICSI does not improve live birth rates compared to conventional IVF and should not be used routinely [8].

Third, a large database study found that all modes of cesarean delivery are associated with an increased risk of new-onset postpartum psychiatric conditions, warranting closer surveillance in this population [9].

Fourth, preclinical data suggests a low-dose magnesium sulfate regimen may be as effective as higher doses for fetal neuroprotection in the setting of inflammation, supporting the need for clinical trials on reduced-duration protocols [7].

And finally, new research into ovarian cancer has identified the stromal protein POSTN as a key mediator of immunosuppression and PARP inhibitor resistance, offering a potential new therapeutic target [3].

That's your roundup for This Week in Obstetrics & Gynecology. The full transcript and references are available on the episode page in your AudioScholar library. This is an AI-curated summary — for clinical decisions, always consult primary sources and current guidelines. See you next week.